NXL:NASDAQNexalin Technology, Inc. Analysis

Price is hovering just above its 20‑day SMA (0.452) but remains well below the 200‑day SMA (0.739), indicating long‑term weakness. The MACD has turned bearish (histogram –0.0002) and RSI sits at a neutral 48.9, while volume is decreasing, suggesting limited buying pressure. On the fundamentals side, the company reports a 63.6% revenue decline, a massive operating loss (‑141.8% margin), negative EPS, and cash burn exceeding $5 M, yet it holds $2.7 M in cash and no debt. Volatility is extreme (119% 30‑day) with a beta of 2.64, and the stock has experienced an 82.7% drawdown, flagging high market risk. Recent material news includes an acquisition of an AI‑integrated remote‑patient monitoring platform and supportive legislative language for neurostimulation research, which could provide a catalyst if the upcoming FDA trial succeeds.